- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07818473
Conventional vs Biologic Therapy in Pediatric IBD
Effectiveness, Safety, and Adverse Events of Conventional and Biologic Therapy in Pediatric Inflammatory Bowel Disease
Study Overview
Status
Detailed Description
Pediatric-onset inflammatory bowel disease differs from adult-onset disease in phenotype, disease extent, and long-term prognosis. Conventional therapy (5-aminosalicylates, corticosteroids, and immunomodulators) and biologic therapy (mainly anti-TNFα agents) are used for induction and maintenance of remission.
This observational cohort study will include pediatric patients with confirmed Crohn's disease, ulcerative colitis, or IBD-unclassified. Patients will be classified into conventional therapy and biologic therapy groups. Clinical remission, response rates, steroid-free remission, adverse events, and growth parameters will be assessed over a 12-month period.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Elizabeth M lshak, Resident
- Phone Number: 01221541345
- Email: elithabeth.17289856@med.aun.edu.eg
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- - Confirmed diagnosis of Crohn's disease, ulcerative colitis, or IBD-unclassified according to revised Porto criteria
- Age at diagnosis less than 18 years
- Receipt of conventional therapy and/or biologic therapy for a minimum evaluable treatment duration
- Availability of adequate medical records
- Written informed consent (for prospective component)
Exclusion Criteria:
- - Incomplete medical records precluding assessment of primary endpoints
- Age more than 18 years
- Discontinuation of follow-up before a minimum evaluable treatment period
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Conventional Therapy
Patients managed with 5-aminosalicylates, corticosteroids, and/or immunomodulators without biologic exposure during the observation period.
|
|
Biologic Therapy
Patients who received biologic therapy (with or without concomitant conventional agents) during the observation period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical remission rate
Time Frame: At week 8-12, 6 months, and 12 months
|
Proportion of patients achieving clinical remission at week 8-12, 6 months, and 12 months, defined as PCDAI ≤ 10 for Crohn's disease or PUCAI < 10 for ulcerative colitis.
|
At week 8-12, 6 months, and 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical response rate
Time Frame: At week 8-12, 6 months, and 12 months
|
Proportion of patients achieving clinical response, defined as a decrease from baseline of ≥12.5 points in PCDAI (Crohn's disease) or ≥20 points in PUCAI (ulcerative colitis).
|
At week 8-12, 6 months, and 12 months
|
|
Steroid-free remission rate
Time Frame: At 12 months
|
Proportion of patients in clinical remission without systemic corticosteroid use.
|
At 12 months
|
|
Incidence of adverse events
Time Frame: Through 12 months
|
Proportion of patients experiencing adverse events (infusion/injection reactions, infections, hematologic abnormalities, hepatotoxicity), graded according to CTCAE-adapted criteria
|
Through 12 months
|
|
Change in growth parameters
Time Frame: From baseline to 12 months
|
Change in height z-score, weight z-score, and BMI z-score from baseline.
|
From baseline to 12 months
|
|
Treatment escalation or switch rate
Time Frame: Through 12 months
|
Proportion of patients requiring treatment escalation or switching between conventional and biologic agents.
|
Through 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Nafisa H Abdel-Aziz, prof, pediatrics Department, Assiut University Hospitals
Publications and helpful links
General Publications
- Van Limbergen J, Russell RK, Drummond HE, Aldhous MC, Round NK, Nimmo ER, Smith L, Gillett PM, McGrogan P, Weaver LT, Bisset WM, Mahdi G, Arnott ID, Satsangi J, Wilson DC. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008 Oct;135(4):1114-22. doi: 10.1053/j.gastro.2008.06.081. Epub 2008 Jul 3.
- Kuenzig ME, Fung SG, Marderfeld L, Mak JWY, Kaplan GG, Ng SC, Wilson DC, Cameron F, Henderson P, Kotze PG, Bhatti J, Fang V, Gerber S, Guay E, Kotteduwa Jayawarden S, Kadota L, Maldonado D F, Osei JA, Sandarage R, Stanton A, Wan M; InsightScope Pediatric IBD Epidemiology Group; Benchimol EI. Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review. Gastroenterology. 2022 Apr;162(4):1147-1159.e4. doi: 10.1053/j.gastro.2021.12.282. Epub 2022 Jan 5.
- Sykora J, Pomahacova R, Kreslova M, Cvalinova D, Stych P, Schwarz J. Current global trends in the incidence of pediatric-onset inflammatory bowel disease. World J Gastroenterol. 2018 Jul 7;24(25):2741-2763. doi: 10.3748/wjg.v24.i25.2741.
- Sauer CG, Kugathasan S. Pediatric inflammatory bowel disease: highlighting pediatric differences in IBD. Gastroenterol Clin North Am. 2009 Dec;38(4):611-28. doi: 10.1016/j.gtc.2009.07.010.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IBD-Pediatric-Therapy-Assiut-2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.